CLAIMS

1. Use of a combination in the manufacture of a medicament for ~~A method of increasing a plasma level of tetrabenazine, alpha-dihydrotetrabenazine, or beta-dihydrotetrabenazine in~~ treating a human being in need of treatment with tetrabenazine, wherein the combination comprises:~~comprising: co-administering~~ 1) an enantiomeric excess of *R*-bupropion or an enantiomeric excess of *S*-bupropion, and 2) tetrabenazine, alpha-dihydrotetrabenazine, or beta-dihydrotetrabenazine~~ to the human being for at least 8 consecutive days, wherein the human being is in need of treatment with tetrabenazine, alpha-dihydrotetrabenazine, or beta-dihydrotetrabenazine, wherein the C_{max} of tetrabenazine, the C_{max} of alpha-dihydrotetrabenazine, or the C_{max} of beta-dihydrotetrabenazine is increased at least 5 fold in the human being on the eighth day that *R*-bupropion tetrabenazine, alpha-dihydrotetrabenazine, or beta-dihydrotetrabenazine are co-administered~~.

2. The use of claim 1, wherein the human being is suffering from~~A method of treating~~ Huntington's disease or chorea associated with Huntington's disease~~ comprising: co-administering 1) an enantiomeric excess of *R*-bupropion, and 2) tetrabenazine, alpha-dihydrotetrabenazine, or beta-dihydrotetrabenazine to the human being for at least 8 consecutive days~~.

3. The use of claim 1, wherein the human being is suffering from~~A method of treating~~ agitation in Alzheimer's disease~~ comprising: co-administering 1) an enantiomeric excess of *R*-bupropion, and 2) tetrabenazine, alpha-dihydrotetrabenazine, or beta-dihydrotetrabenazine to the human being for at least 8 consecutive days~~.

4. The use of claim1, wherein the human being is suffering from~~A method of treating~~ depression~~ comprising: co-administering 1) an enantiomeric excess of *R*-bupropion, and 2) tetrabenazine, alpha-dihydrotetrabenazine, or beta-dihydrotetrabenazine to the human being for at least 8 consecutive days~~.

5. The ~~method~~use of claim 1, 2, 3, or 4, wherein the medicament inlcudes about 100 mg to about 110 mg of *R*-bupropion or *S*-bupropion~~ is administered twice a day to the human being for at least 8 consecutive days~~.

~~6. A method of increasing a plasma level of tetrabenazine, alpha-dihydrotetrabenazine, or beta-dihydrotetrabenazine in a human being comprising: co-administering 1) an enantiomeric excess of *S*-bupropion, and 2) tetrabenazine, alpha-dihydrotetrabenazine, or~~

~~beta-dihydrotetrabenazine to the human being for at least 8 consecutive days, wherein the human being is in need of treatment with tetrabenazine, alpha-dihydrotetrabenazine, or beta-dihydrotetrabenazine, wherein the C_{max} of tetrabenazine, the C_{max} of alpha-dihydrotetrabenazine, or the C_{max} of beta-dihydrotetrabenazine is increased at least 5 fold in the human being on the eighth day that *S*-bupropion tetrabenazine, alpha-dihydrotetrabenazine, or beta-dihydrotetrabenazine are co-administered.~~

~~7. A method of treating agitation in Alzheimer's disease comprising: co-administering 1) an enantiomeric excess of *S* bupropion, and 2) tetrabenazine, alpha-dihydrotetrabenazine, or beta-dihydrotetrabenazine to the human being for at least 8 consecutive days.~~

~~8. A method of treating depression comprising: co-administering 1) an enantiomeric excess of *S* bupropion, and 2) tetrabenazine, alpha-dihydrotetrabenazine, or beta-dihydrotetrabenazine to the human being for at least 8 consecutive days.~~

~~9. The method of claim 1, 2, 3, or 4, wherein about 100 mg to about 110 mg of *S*-bupropion is administered twice a day to the human being for at least 8 consecutive days.~~

~~10.~~6. The method of claim 4 ~~or 8~~, wherein the depression is treatment-resistant depression or major depression.

~~11.~~7. The ~~method~~use of claim 1, 2, 3, 4, or 5, ~~6, 7, 8, 9, or 10,~~ wherein the medicament includes about 5 mg to about 20 mg of a tetrabenazine ~~is administered twice a day to the human being for at least 8 consecutive days~~.

~~12. The method of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11, wherein the AUC of alpha-dihydrotetrabenazine on day 8 is at least 5 times the AUC that would be achieved by administering the same amount of tetrabenazine, alpha-dihydrotetrabenazine, or beta-dihydrotetrabenazine to the human being for at least 8 consecutive days to the human being without administering the bupropion.~~

~~13. The method of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11, wherein the AUC of beta-dihydrotetrabenazine on day 8 is at least 15 times the AUC that would be achieved by administering the same amount of tetrabenazine, alpha-dihydrotetrabenazine, or beta-dihydrotetrabenazine to the human being for at least 8 consecutive days to the human being without administering the bupropion.~~

~~14. The method of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11, wherein the C_{max} of alpha-dihydrotetrabenazine on day 8 is at least twice the C_{max} that would be achieved by administering the same amount of tetrabenazine, alpha-dihydrotetrabenazine, or beta-dihydrotetrabenazine to the human being for at least 8 consecutive days to the human being without administering the bupropion.~~

~~15. The method of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11, wherein the C_{max} of beta-dihydrotetrabenazine on day 8 is at least 5 times the C_{max} that would be achieved by administering the same amount of tetrabenazine, alpha-dihydrotetrabenazine, or beta-dihydrotetrabenazine to the human being for at least 8 consecutive days to the human being without administering the bupropion.~~

8. The use of claim 1, 2, 3, or 4, wherein the medicament includes about 90 mg to about 140 mg of *R*-bupropion or *S*-bupropion.

9. The use of claim 1, 2, 3 or 4, wherein the wherein the *R*-bupropion has an enantiomeric excess of at least 95% or the *S*-bupropion has an enantiomeric excess of at least 95%.

10. The use of claim 1, 2, 3, or 4, wherein the medicament includes the *R*-bupropion or the *S*-bupropion, and the tetrabenazine, the alpha-dihydrotetrabenazine, or the beta-dihydrotetrabenazine in a single dosage form.

11. The use of claim 1, 2, 3, or 4, wherein the medicament includes the *R*-bupropion or the *S*-bupropion, and the tetrabenazine, the alpha-dihydrotetrabenazine, or the beta-dihydrotetrabenazine in separate dosage forms.

12. The use of claim 1, 2, 3, or 4, wherein the medicament is formulated for sustained release of the *R*-bupropion or the *S*-bupropion.

13. The use of claim 1, 2, 3, or 4, wherein the medicament is formulated for immediate release of the tetrabenazine, the alpha-dihydrotetrabenazine, or the beta-dihydrotetrabenazine.

14. A dosage form, comprising 1) an enantiomeric excess of *R*-bupropion or an enantiomeric excess of *S*-bupropion, and 2) tetrabenazine, alpha-dihydrotetrabenazine, or beta-dihydrotetrabenazine.

15. The dosage form of claim 14, comprising about 5 mg to about 20 mg of the tetrabenazine.

16. The dosage form of claim 14 or 15, comprising about 10 mg to about 15 mg of the tetrabenazine.

17. The dosage form of claim 14, having a weight ratio of tetrabenazine, alpha-dihydrotetrabenazine, or beta-dihydrotetrabenazine to *R*-bupropion or *S*-bupropion that is about 0.1 to about 0.3.

18. The dosage form of claim 14, 15, or 16, comprising about 90 mg to about 110 mg of the *R*-bupropion or the *S*-bupropion.

19. The dosage form of claim 14, 15, or 16, comprising about 90 mg to about 140 mg of the *R*-bupropion or the *S*-bupropion.

20. The dosage form of claim 14, 15, or 16, wherein the dosage form has an enantiomeric excess of *R*-bupropion and the *R*-bupropion has an enantiomeric excess of at least 95%.

21. The dosage form of claim 14, 15, or 16, wherein the dosage form has an enantiomeric excess of *S*-bupropion and the *S*-bupropion has an enantiomeric excess of at least 95%.

22. The dosage form of claim 14, 15, or 16, wherein the *R*-bupropion or the *S*-bupropion, and the tetrabenazine, the alpha-dihydrotetrabenazine, or the beta-dihydrotetrabenazine, are in a single dosage form.

23. The dosage form of claim 14, 15, or 16, wherein the *R*-bupropion or the *S*-bupropion is formulated for sustained release.

24. The dosage form of claim 14, 15, or 16, wherein the tetrabenazine, the alpha-dihydrotetrabenazine, or the beta-dihydrotetrabenazine is formulated for immediate release.

25. The dosage form of claim 14, 15, or 16, wherein the dosage form is formulated for oral administration to the human being.

26. The dosage form of claim 14, 15, or 16, comprising about 70 mg to about 140 mg of the *R*-bupropion or the *S*-bupropion.

27. The dosage form of claim 14, 15, or 16, comprising about 70 mg to about 100 mg of the bupropion.

28. The dosage form of claim 14, 15, or 16, comprising about 100 mg to about 140 mg of the bupropion.

29. The dosage form of claim 14 or 15, comprising about 9 mg to about 12 mg of the tetrabenazine.

30. The dosage form of claim 14, 15, or 16, comprising about 12 mg to about 15 mg of the tetrabenazine.